Effectiveness of tacrolimus concomitant with biological disease-modifying antirheumatic drugs in patients with rheumatoid arthritis
Modern Rheumatology · 2023
DOI: 10.1093/mr/roac025 ↗Kurz gefasst
Fachartikel in der Zeitschrift Modern Rheumatology, 2023. Verfasst von Kenya Terabe und 16 weiteren Autor:innen. Beteiligte Einrichtung: Department of Orthopedic Surgery, Nagoya University Graduate School of Medicine, Nagoya, Japan. Hauptthemen laut MEDLINE: Antirheumatic Agents, Arthritis, Rheumatoid. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 40 Literaturangaben.
Abstract (Originalsprache)
Objectives
The study aimed to investigate the effectiveness and tolerance of biological disease-modifying antirheumatic drugs (bDMARDs) therapy administered concomitantly with tacrolimus (TAC) treatment in patients with rheumatoid arthritis.
Methods
2792 patients who underwent therapy with five bDMARDs (etanercept: ETN, adalimumab, golimumab, tocilizumab, and abatacept: ABT) were enrolled. Among the study subjects, 1582 were concomitant methotrexate (MTX group), 147 were concomitant TAC (TAC group), and 1063 were non-concomitant MTX and TAC (non-MTX/TAC group). The primary outcome was the incident rate of discontinuation of bDMARDs by adverse events (AEs) or loss of efficacy.
Results
Concerning the analysis for each reasons of discontinuation, including AEs and loss of efficacy, the hazards ratio (HR) was significantly lower in the TAC group than in non-MTX/TAC groups (AEs: HR = 0.39, 95% confidence interval, 0.23–0.68, loss of efficacy: HR = 0.49, 95% confidence interval, 0.30–0.78). The loss of efficacy with the use of ETN and ABT was lower in the TAC group than in non-MTX/TAC groups. Concomitant TAC did not induce elevated risk for discontinuation of AEs in all bDMARD analyses.
Conclusions
Concomitant TAC with ABT or ETN showed higher retention rates than bDMARDs therapy without TAC or MTX. AEs did not increase over long-term observation.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Orthopedic Surgery, Nagoya University Graduate School of Medicine, Nagoya, Japan.
- Department of Rheumatology, Toyohashi Municipal Hospital, Toyohashi, Japan.
- Department of Orthopedic Surgery, Toyota Kosei Hospital, Toyota, Japan.
- Department of Rheumatology, Tokyo Shinjuku Medical Center, Tokyo, Japan.
- Department of Orthopedic Surgery, Anjo Kosei Hospital, Anjo, Japan.
- Department of Orthopedic Surgery, Konan Kosei Hospital, Konan, Japan.
ORCID-Profile: Kenya Terabe, Shiro Imagama
Zitieren
APA
Terabe, K., Takahashi, N., Asai, S., Hirano, Y., Kanayama, Y., Yabe, Y., Oguchi, T., Fujibayashi, T., Ishikawa, H., Hanabayashi, M., Hattori, Y., Suzuki, M., Kishimoto, K., Ohashi, Y., Imaizumi, T., Imagama, S., & Kojima, T. (2023). Effectiveness of tacrolimus concomitant with biological disease-modifying antirheumatic drugs in patients with rheumatoid arthritis. Modern Rheumatology. https://doi.org/10.1093/mr/roac025
Vancouver
Terabe K, Takahashi N, Asai S, Hirano Y, Kanayama Y, Yabe Y, et al. Effectiveness of tacrolimus concomitant with biological disease-modifying antirheumatic drugs in patients with rheumatoid arthritis. Modern Rheumatology. 2023. doi:10.1093/mr/roac025
BibTeX
@article{Terabe2023,
author = {Terabe, Kenya and Takahashi, Nobunori and Asai, Shuji and Hirano, Yuji and Kanayama, Yasuhide and Yabe, Yuichiro and Oguchi, Takeshi and Fujibayashi, Takayoshi and Ishikawa, Hisato and Hanabayashi, Masahiro and Hattori, Yosuke and Suzuki, Mochihito and Kishimoto, Kenji and Ohashi, Yoshifumi and Imaizumi, Takahiro and Imagama, Shiro and Kojima, Toshihisa},
title = {Effectiveness of tacrolimus concomitant with biological disease-modifying antirheumatic drugs in patients with rheumatoid arthritis},
journal = {Modern Rheumatology},
year = {2023},
doi = {10.1093/mr/roac025}
}
EUVIMED